Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- (-) Compliance and enforcement (70)
- Advertising (278)
- COVID-19 (163)
- Safety monitoring and information (102)
- Legislation (95)
- Manufacturing (55)
- Vaping hub (55)
- Labelling and packaging (37)
- Import and export (28)
- Scheduling (national classification system) (27)
- Medicinal cannabis hub (25)
- Sunscreens (16)
- Weight loss products (15)
- Shortages and supply disruptions (14)
- Committees and advisory bodies (9)
- Cosmetics (5)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
113 result(s) found, displaying 101 to 113
-
Regulatory decision noticesPrevention notice under section 42DKB of the Therapeutic Goods Act 1989.
-
Media releasesConsumers are advised to be cautious about ivermectin products that are sold by unverified online stores.
-
Media releasesThe TGA has issued two infringement notices totalling $26,640 to a Sydney-based company for alleged unlawful advertising of a TENS device.
-
Media releasesThe Federal Court of Australia has made orders restraining MMS Australia from advertising and supplying goods containing certain potentially dangerous substances until a further hearing next week
-
Media releasesThe TGA has commenced work on a sector-wide compliance activity relating to the advertising of bioresonance devices
-
News articlesChanges will be made to the regulation of nappy rash products on 1 January 2020
-
Media releasesThe Federal Court has imposed substantial penalties on Peptide Clinics Australia
-
News articlesIndications proposed by industry during the 2017 public comment period have been published
-
Regulatory decision noticesTGA issues advertising direction
-
Safety updatesThe TGA completed a desktop review of selected listed sunscreen products.
-
Regulatory decision noticesThis instrument applies to an application to list a complementary medicine under section 26AE of the Act.
-
Regulatory decision noticesThis instrument applies to an application to register a complementary medicine
-
Regulatory decision noticesGarcinia gummi-gutta, also commonly known as Garcinia cambogia, can be used as an ingredient in lower-risk (listed) medicines.